

Drug conjugates of formula $[D-(X)_b-(AA)_w-(L)-]_n\text{-Ab}$ wherein: D is a drug moiety having the following formula (I) or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof, wherein: A is selected from (II) and (III) R_1 , R_2 and R_3 is H, OR_a , $OCOR_a$, $OCO-OR_a$, alkyl, alkenyl, alkynyl, etc; R_3' is, COR_a , $COOR_a$, $CONR_aR_b$, etc; each of R_4 to R_{10} and R_{12} is alkyl, alkenyl or alkynyl; R_{11} is H, COR_a , $COOR_a$, alkyl, alkenyl or alkynyl, or R_{11} and $R_{12}+N+C$ atoms to which they are attached may form a heterocyclic group; each of R_{13} and R_{14} is H, COR_a , $COOR_a$, alkyl, alkenyl or alkynyl; each R_a and R_b is H, alkyl, alkenyl, alkynyl, etc.; each dotted line represents an optional additional bond; X is an extending group; AA is an amino acid unit; L is a linker group; w is 0 to 12; b is 0 or 1; A bis a moiety comprising at least one antigen binding site, and n is the ratio of the group $[D-(X)_b-(AA)_w-(L)-]$ to the moiety comprising at least one antigen binding site and is in the range from 1 to 20, are useful in the treatment of cancer.